SFA Therapeutics Harnesses Power Of Bacterial Metabolites To Treat Inflammatory Disease

Emerging Company Profile: The US biotech is advancing its lead candidate into a Phase Ib psoriasis trial as it works to validate its bacterial metabolite-based drug platform, which exemplifies a new generation of microbiome technology.